Latest & greatest articles for baclofen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on baclofen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on baclofen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for baclofen

1. Baclofen for alcohol withdrawal. (Abstract)

Baclofen for alcohol withdrawal. Alcohol withdrawal syndrome (AWS) is a distressing and life-threatening condition that usually affects people who are alcohol dependent when they discontinue or decrease their alcohol consumption. Baclofen shows potential for rapidly reducing symptoms of severe AWS in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original (...) Cochrane Review first published in 2011 and last updated in 2017.To assess the efficacy and safety of baclofen for people with AWS.We updated our searches of the following databases to June 2019: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about

2020 The Cochrane database of systematic reviews

2. A Systematic Review of the Effectiveness of Oral Baclofen in the Management of Hiccups in Adult Palliative Care Patients. (Abstract)

A Systematic Review of the Effectiveness of Oral Baclofen in the Management of Hiccups in Adult Palliative Care Patients. Hiccup is a recognised symptom amongst the palliative care population. It can be debilitating, with significant impact on quality of life. The pathophysiology is poorly understood and the list of aetiological factors is extensive. The current treatment recommendations are based on a small body of evidence and there remains uncertainty regarding optimal management. The aim (...) of this study was to systematically review the evidence for oral baclofen in the management of hiccups in adult palliative care patients. A search was conducted using MEDLINE, Embase, the Cochrane library and CINAHL, as well as a hand search and review of the grey literature. Relevant articles were identified using pre-defined eligibility criteria. Quality assessment was guided by the SIGN grading system, CASP, Hawker et al's checklist and Cochrane's risk of bias tool. A narrative approach was used for data

2020 Journal of pain & palliative care pharmacotherapy

3. Baclofen (Baclocur) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption

Baclofen (Baclocur) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption Prescrire IN ENGLISH - Spotlight ''Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption'', 1 February 2020 {1} {1} {1} | | > > > Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :   (...) |   |   |   |   |   |   |   |   |  Spotlight Baclofen (Baclocur°) and alcohol dependence. At moderate doses, a modest aid in controlling alcohol consumption FEATURED REVIEW The GABA analogue baclofen (Baclocur°, Ethypharm), used since the 1970s as a muscle relaxant, has now been granted marketing authorisation in France for the reduction of alcohol consumption in alcohol-dependent patients in whom the other drug treatments have

2020 Prescrire

4. Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. (Full text)

Association of Baclofen With Encephalopathy in Patients With Chronic Kidney Disease. At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidney disease (CKD).To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers.Retrospective (...) population-based cohort study in Ontario, Canada (2007-2018) using linked health care data. Participants comprised 15 942 older adults (aged 66 years or older) with CKD (defined as an estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 but not receiving dialysis). The primary cohort was restricted to patients who were newly prescribed baclofen; participants in the secondary cohort were new users and nonusers.Prescription for oral baclofen greater than or equal to 20 mg per day vs less than 20

2019 JAMA PubMed abstract

5. [The efficacy of baclofen in alcohol dependence]. (Abstract)

[The efficacy of baclofen in alcohol dependence]. In the past years numerous studies have investigated the efficacy of baclofen for alcohol dependence. After publication of several reviews a number of new randomized controlled trials have been published. Two recent meta-analyses, based on largely the same studies, reported contrary results. One meta-analysis showed a positive effect on time to relapse and abstinence at endpoint. The other meta-analysis did not show an effect on the primary (...) outcome measures.
AIM: To clarify the clinical relevance of the effect of baclofen on alcohol use in patients with a disorder in the use of alcohol, in the light of the positive and the negative meta-analysis.
METHOD: A systematic literature search using Medline, Embase and PsycINFO (Prisma guideline).
RESULTS: We found 16 randomized controlled trials in which the effect of baclofen was studied. Seven of them showed a significant positive effect of baclofen on (one or more

2019 Tijdschrift Voor Psychiatrie

6. Intrathecal baclofen versus selective dorsal rhizotomy for children with cerebral palsy who are nonambulant: a systematic review. (Abstract)

Intrathecal baclofen versus selective dorsal rhizotomy for children with cerebral palsy who are nonambulant: a systematic review. Cerebral palsy (CP) is the most common childhood physical disability. Historically, children with hypertonia who are nonambulatory (Gross Motor Function Classification System [GMFCS] level IV or V) were considered candidates for intrathecal baclofen (ITB) therapy to facilitate care and mitigate discomfort. Selective dorsal rhizotomy (SDR) was often reserved

2019 Journal of neurosurgery. Pediatrics

7. The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial (Full text)

The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial Intrathecal baclofen treatment is used for the treatment of dystonia in patients with severe dyskinetic cerebral palsy; however, the current level of evidence for the effect is low. The primary aim of this study was to provide evidence for the effect of intrathecal baclofen treatment on individual goals in patients with severe dyskinetic cerebral palsy.This multicenter, randomized, double-blind, placebo-controlled (...) trial was performed at 2 university medical centers in the Netherlands. Patients with severe dyskinetic cerebral palsy (Gross Motor Functioning Classification System level IV-V) aged 4 to 24 years who were eligible for intrathecal baclofen were included. Patients were assigned by block randomization (2:2) for treatment with intrathecal baclofen or placebo for 3 months via an implanted microinfusion pump. The primary outcome was goal attainment scaling of individual treatment goals (GAS T score

2019 EvidenceUpdates PubMed abstract

8. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. (Abstract)

Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. A systematic review of the current literature on the efficacy of baclofen, particularly the effect of dosing, for the treatment of alcohol dependence (AD) is missing. We therefore conducted a systematic review and meta-analysis of currently available randomized placebo-controlled trials (RCTs). A systematic literature search for RCTs in AD patients (...) comparing baclofen to placebo was performed in September 2017. The effect of baclofen treatment, and the moderating effects of baclofen dosing (low-dose (LDB) 30-60 mg versus high-dose (HDB) targeted as >60 mg/day), and the amount of alcohol consumption before inclusion were studied. Three treatment outcomes were assessed: time to lapse (TTL), percentage days abstinent (PDA), and percentage of patients abstinent at end point (PAE). 13 RCTs from 39 records were included. Baclofen was superior to placebo

2019 European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

9. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity (Full text)

Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL). SISTERS (Spasticity In Stroke-Randomized Study) was a randomized, controlled, open-label, multicenter, phase 4 study to evaluate ITB therapy versus conventional medical management (CMM) with oral

2019 EvidenceUpdates PubMed abstract

10. Palliative cancer care - pain: What issues should I consider before prescribing baclofen?

Palliative cancer care - pain: What issues should I consider before prescribing baclofen? Baclofen | Prescribing information | Palliative cancer care - pain | CKS | NICE Search CKS… Menu Baclofen Palliative cancer care - pain: What issues should I consider before prescribing baclofen? Last revised in October 2016 What issues should I consider before prescribing baclofen? Sedation, drowsiness and nausea are commonly reported adverse effects. Do not stop baclofen abruptly; sudden withdrawal can (...) lead to serious psychiatric adverse effects such as agitation, confusion, hallucinations, psychosis, mania, paranoia, convulsions, tachycardia, and hyperthermia. Gradually reduce the dose over 1–2 weeks, or over a longer period if adverse effects occur during withdrawal. Consider using diazepam rather than baclofen in people with: Active (or history of) peptic ulceration, as baclofen stimulates gastric acid secretion. Psychiatric disorders, such as psychosis, schizophrenia, depression, or mania

2019 NICE Clinical Knowledge Summaries

11. Baclofen for alcohol use disorder. (Full text)

Baclofen for alcohol use disorder. Alcohol use disorder (AUD) and alcohol-related impairments belong to the most widespread psychiatric disorders leading to specific psychophysical, affective and cognitive symptoms and consequences for psychosocial well-being and health. Alcohol consumption is increasingly becoming a problem in many developing regions and AUD prevalence is estimated at 4.1% worldwide, with highest prevalence in European countries (7.5%), and the North America (6.0 (...) %). Therapeutic approaches, including pharmacotherapy, play an important role in treating patients with AUD.To assess the efficacy and safety of baclofen for treating people with AUD, who are currently drinking, with the aim of achieving and maintaining abstinence or reducing alcohol consumption.We searched the Cochrane Drugs and Alcohol Specialised Register, CENTRAL, MEDLINE, Embase, two further databases and two clinical trials registries, conference proceedings, and the reference lists of retrieved

2018 Cochrane PubMed abstract

12. Alcohol dependence: the risks of high-dose baclofen

Alcohol dependence: the risks of high-dose baclofen Prescrire IN ENGLISH - Spotlight ''Alcohol dependence: the risks of high-dose baclofen '', 1 November 2018 {1} {1} {1} | | > > > Alcohol dependence: the risks of high-dose baclofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Alcohol dependence: the risks of high-dose baclofen With high-dose (...) baclofen, there is an increased risk of epilepsy, infection, myocardial infarction or suicidal thoughts. Baclofen has been used as a muscle relaxant since the 1970s. In France, it has also been used orally since the 2000s, at higher doses, to reduce alcohol consumption or to help maintain abstinence among alcohol-dependent patients. At present, its use in alcohol dependence is governed by a temporary recommendation for use issued by the French Health Products Safety Agency (Agence française du

2018 Prescrire

13. Effect of continuous intrathecal baclofen therapy in children: a systematic review. (Full text)

Effect of continuous intrathecal baclofen therapy in children: a systematic review. To investigate the effects of continuous intrathecal baclofen (ITB) therapy in children with cerebral palsy (CP) and other neurological conditions.This systematic review was conducted using standardized methodology, searching four electronic databases (PubMed, Embase, CINAHL, Cochrane Library) for relevant literature published between inception and September 2017. Included studies involved continuous ITB (...) may be difficult to realize, national and international collaborations may provide opportunities. Also, multicentre prospective cohort studies with a long-term follow-up, employing harmonized outcome measures, can offer prospects to expand our knowledge of the effects of continuous ITB therapy in children.There is low-level evidence for continuous intrathecal baclofen (ITB) in children with cerebral palsy. Continuous ITB is effective in reducing spasticity and dystonia in non-controlled cohort

2018 Developmental Medicine and Child Neurology PubMed abstract

14. Baclofen

Baclofen Top results for baclofen - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for baclofen The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

15. Baclofen for alcohol use disorder-a systematic meta-analysis. (Abstract)

Baclofen for alcohol use disorder-a systematic meta-analysis. To evaluate the efficacy and tolerability of baclofen vs. placebo for long-term treatment of alcohol use disorder.Systematic review and meta-analysis following methods of the Cochrane Collaboration Handbook (PROSPERO registration: CRD42017073663). Primary outcome was the random-effects summary estimate of all standardized mean differences (SMDs), as calculated from the primary outcomes of each study.Fourteen double-blind RCTs (1522 (...) patients) were included. Heterogeneity was substantial for most analyses (I2 about 75%). Baclofen showed a small, but not statistically significant superiority over placebo: SMD = 0.22 ([95% CI: -0.03; 0.47], P = 0.09). This result was supported by a leave-one-out-analysis, and Orwin's fail-safe N, by predefined secondary analyses (on abstinence rates and amount of drinking), and by a post hoc-analysis of high-dose studies (>80 mg/day). An analysis of low risk of bias studies (SMD = 0.10 [-0.20; 0.41

2018 Acta Psychiatrica Scandinavica

16. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. (Abstract)

Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. There are a limited number of pharmacotherapies licensed for alcohol use disorders (AUDs). Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment. A meta-analysis of randomized controlled trials (RCTs) was conducted to determine the efficacy of baclofen in reducing drinking behaviour, craving, depression and anxiety compared (...) with placebo.Random-effects meta-analyses were computed on outcome data from 12 RCTs comparing baclofen with placebo. Included RCTs provided data on at least one of the primary outcome measures (drinking-related: heavy drinking days, abstinent days, abstinence rates) or secondary outcome measures (craving, anxiety, depression).Baclofen had a significant effect on abstinence rates when using intention-to-treat analysis [total n baclofen = 307, total n control = 283: odds ratio (OR) = 2.67, 95% confidence interval

2018 Addiction (Abingdon, England)

17. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS) (Full text)

Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS) Intrathecal baclofen (ITB) is a treatment option for patients with severe poststroke spasticity (PSS) who have not reached their therapy goal with other interventions.'Spasticity In Stroke-Randomised Study' (SISTERS) was a randomised, controlled, open-label, multicentre phase IV study to evaluate the efficacy

2018 EvidenceUpdates PubMed abstract

18. Cerebral palsy: Baclofen

Cerebral palsy: Baclofen Baclofen | Prescribing information | Cerebral palsy | CKS | NICE Search CKS… Menu Baclofen Cerebral palsy: Baclofen June 2019 Baclofen Contraindications and cautions Do not prescribe baclofen to people with: Rare hereditary conditions of porphyria, galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. Active peptic ulceration. Prescribe baclofen with caution to people: With cerebrovascular disease. With Parkinson's disease (...) . With respiratory, hepatic, or renal impairment. With a history of peptic ulceration. With bladder sphincter hypertonia. With epilepsy. With severe psychiatric disorders — may be exacerbated by baclofen. Taking certain . Pregnancy: the manufacturer advises use only if the potential benefit outweighs risk as studies in animals have shown reproductive toxicity. Driving and using machinery: baclofen may cause drowsiness and may affect performance of skilled tasks (such as driving). The effects of alcohol

2018 NICE Clinical Knowledge Summaries

19. Multiple sclerosis: Baclofen

Multiple sclerosis: Baclofen Baclofen | Prescribing information | Multiple sclerosis | CKS | NICE Search CKS… Menu Baclofen Multiple sclerosis: Baclofen Last revised in October 2019 Baclofen What doses of baclofen are indicated for spasticity? The dose of baclofen often needs adjustment to suit each person, but a typical regimen is: Initial dose: 5 mg three times a day. Titration: gradually increase the dose every three days. Typical maintenance dose is 60 mg daily in divided doses. Maximum (...) stopping treatment. [ ; ] What are the contraindications for baclofen? Do not prescribe baclofen to people with: Rare hereditary conditions of porphyria, galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption. Active peptic ulceration. [ ; ] What are the cautions when using baclofen? Prescribe baclofen with caution to people: With cerebrovascular disease. With Parkinson's disease. With respiratory, hepatic or renal impairment. With a history of peptic ulceration

2018 NICE Clinical Knowledge Summaries

20. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. (Abstract)

Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. The pharmacological properties of baclofen, a GABA(B) receptor agonist, have led to investigation of its use for the off-label treatment of alcohol dependence. Literature examining the role of baclofen in alcohol dependence suggests that it may be a useful medication in the treatment armamentarium with an additional benefit of promoting abstinence and reducing alcohol-associated cravings (...) and anxiety. We conducted a systematic review of prospective, randomized controlled trials comparing baclofen with placebo for the treatment of alcohol dependence. Four randomized controlled trials were identified but only three met criteria for inclusion. The excluded trial was a post hoc analysis of data collected from an original trial whose primary outcome did not fit our inclusion criteria and was terminated prior to completion. Compared with placebo, subjects randomized to baclofen experienced

2017 CNS drugs